NCT01153698

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Observational Cohort Study to Evaluate the Safety and Efficacy of Switching From Lovenox (Enoxaparin) 40mg to Pradaxa (Dabigatran Etexilate) 220mg in Patients Undergoing Elective Total Hip or Knee Replacement Surgery

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 167 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

an open, prospective, observational study to collect data on safety (major bleeding events) and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to dabigatran etexilate in patients with total knee replacement (TKR) and total hip replacement (THR)

Conditions

• Venous Thromboembolism
• Arthroplasty, Replacement

Interventions

Type	Name	Description
DRUG	dabigatran	anticoagulation

Timeline

• Start date: 2010-08-01
• Primary completion: 2011-12-21
• Completion: 2011-12-21
• First posted: 2010-06-30
• Last updated: 2023-10-03
• Results posted: 2013-01-04

Locations

7 sites across 1 country: Austria